Announcements Trials
Browse Landscape

Phase

Phase 4 2Phase 2 1

Status

Unknown 4

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 3Observational 1

Sponsor

Cancer Type

Thoracic 4

Conditions

Carcinoma, Non-Small-Cell Lung 44Lung Neoplasms 9Brain Neoplasms 7NSCLC 4Pancreatic Neoplasms 2Neoplasms 2Nasopharyngeal Carcinoma 2Esophageal Neoplasms 2EGF-R Positive Non-Small Cell Lung Cancer 2Adenocarcinoma of Lung 2Adenocarcinoma 2Squamous Cell Carcinoma of Lung 1Plasma EGFR Mutation-positive Lung Cancer 1Non-squamous Non-small Cell Lung Cancer 1Non-small Cell Lung Cancer Metastatic 1Non-Small-Cell Lung 1Neuroma, Acoustic 1Neurofibromatosis 2 1Neoplasms, Second Primary 1Neoplasm Metastasis 1Drug-Related Side Effects and Adverse Reactions 1Bronchial Neoplasms 1Breast Neoplasms 1

Interventions

Pemetrexed 14Carboplatin 13osimertinib 11Drug Therapy 9aflutinib 8Gefitinib 8Radiotherapy 6Docetaxel 6Cisplatin 6pembrolizumab 5anlotinib 5Radiosurgery 5Paclitaxel 5icotinib 4Vinorelbine 4Gemcitabine 4Erlotinib Hydrochloride 4tislelizumab 3camrelizumab 3apatinib 3HM781-36B 3toripalimab 2spartalizumab 2rezivertinib 2dacomitinib 2Tyrosine Kinase Inhibitors 2Thalidomide 2Surgical Procedures, Operative 2S 1 (combination) 2Platinum 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
NSCLC × icotinib × Clear all
NCT04575415 2020-10-20

BELLA

Guangdong Association of Clinical Trials

Unknown
272 enrolled
Thoracic

NSCLC

NCT02404675 2017-07-28

INCREASE

Betta Pharmaceuticals Co., Ltd.

Phase 4 Unknown
240 enrolled
Thoracic

NSCLC

NCT02778893 2016-05-20

Conmana Combined With Thalidomide to Treat NSCLC

Henan Provincial People's Hospital

Phase 4 Unknown
67 enrolled
Thoracic

NSCLC

NCT02272127 2014-10-22

Study of Chemotherapy Plus Icotinib to Treat EGFR Mutation-positive Non-small-cell Lung Cancer

Nanfang Hospital, Southern Medical University

Phase 2 Unknown
100 enrolled
Thoracic

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡